Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial
A Mas, J Rodés, L Sunyer, L Rodrigo, R Planas… - Journal of …, 2003 - Elsevier
Background/Aims: The efficacy and safety of rifaximin in comparison with lactitol in the
treatment of acute hepatic encephalopathy was assessed in a prospective randomized,
double-blind, double-dummy, controlled trial. Methods: A total of 103 patients with grade I–III
acute hepatic encephalopathy were randomized to receive rifaximin (50 patients, 1200
mg/day) or lactitol (53 patients, 60 g/day) for 5–10 days. Changes in the portal-systemic
encephalopathy (PSE) index on entry and at the end of the study were used to evaluate the …
treatment of acute hepatic encephalopathy was assessed in a prospective randomized,
double-blind, double-dummy, controlled trial. Methods: A total of 103 patients with grade I–III
acute hepatic encephalopathy were randomized to receive rifaximin (50 patients, 1200
mg/day) or lactitol (53 patients, 60 g/day) for 5–10 days. Changes in the portal-systemic
encephalopathy (PSE) index on entry and at the end of the study were used to evaluate the …
以上显示的是最相近的搜索结果。 查看全部搜索结果